Phocas Financial Corp. Cuts Position in Elanco Animal Health Incorporated $ELAN

Phocas Financial Corp. trimmed its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 16.9% in the 4th quarter, HoldingsChannel reports. The fund owned 182,755 shares of the company’s stock after selling 37,204 shares during the quarter. Phocas Financial Corp.’s holdings in Elanco Animal Health were worth $4,136,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. AlphaQuest LLC raised its holdings in Elanco Animal Health by 13.7% in the third quarter. AlphaQuest LLC now owns 5,953 shares of the company’s stock worth $120,000 after purchasing an additional 718 shares in the last quarter. Jones Financial Companies Lllp boosted its holdings in shares of Elanco Animal Health by 15.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 6,065 shares of the company’s stock valued at $119,000 after buying an additional 798 shares in the last quarter. US Bancorp DE boosted its holdings in shares of Elanco Animal Health by 1.9% in the 3rd quarter. US Bancorp DE now owns 43,810 shares of the company’s stock valued at $882,000 after buying an additional 824 shares in the last quarter. Whittier Trust Co. of Nevada Inc. grew its position in shares of Elanco Animal Health by 80.3% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock worth $42,000 after buying an additional 900 shares during the last quarter. Finally, Farther Finance Advisors LLC grew its position in shares of Elanco Animal Health by 79.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company’s stock worth $43,000 after buying an additional 951 shares during the last quarter. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ELAN has been the subject of a number of analyst reports. Barclays started coverage on shares of Elanco Animal Health in a research report on Tuesday, December 9th. They set an “overweight” rating and a $30.00 target price for the company. Wall Street Zen raised Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 19th. KeyCorp increased their price objective on Elanco Animal Health from $27.00 to $29.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Weiss Ratings reissued a “sell (d+)” rating on shares of Elanco Animal Health in a research report on Friday, March 27th. Finally, JPMorgan Chase & Co. upped their target price on Elanco Animal Health from $24.00 to $28.00 and gave the company an “overweight” rating in a research report on Thursday, February 19th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $27.67.

Elanco Animal Health Trading Up 0.1%

Shares of Elanco Animal Health stock opened at $23.11 on Monday. The firm’s 50 day simple moving average is $24.56 and its two-hundred day simple moving average is $22.85. The firm has a market capitalization of $11.49 billion, a price-to-earnings ratio of -48.14, a PEG ratio of 2.94 and a beta of 1.88. Elanco Animal Health Incorporated has a 12-month low of $8.02 and a 12-month high of $27.72. The company has a current ratio of 2.17, a quick ratio of 1.08 and a debt-to-equity ratio of 0.60.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Tuesday, February 24th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.11 by $0.02. Elanco Animal Health had a negative net margin of 4.92% and a positive return on equity of 7.16%. The business had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.09 billion. During the same period in the previous year, the firm posted $0.14 earnings per share. The business’s revenue for the quarter was up 12.2% compared to the same quarter last year. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. Analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.